{"description":"This trial is single arm study and it is non-randomized. Overall, if patients did not have enough cells to do two transplants then they only received one transplants. This trial is not a two arm protocol.","eventGroups":[{"deathsNumAffected":6,"deathsNumAtRisk":23,"description":"Patients with Germ Cell Tumors (GCT) treated with one and second autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.\n\nAdverse events are not separable by number of transplants because they were not recorded in to the University of Minnesota's CTMS system. Below you will see AEs for patients with 1 and 2 transplants pooled together.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":23,"seriousNumAffected":8,"seriousNumAtRisk":23,"title":"2 Transplants/1 Transplant Arms (Overall)"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":23,"numEvents":7}],"term":"Relapse"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":23,"numEvents":3}],"term":"Progressive Disease"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":23,"numEvents":1}],"term":"Death"}],"timeFrame":"All-Cause Mortality monitored/assessed for 1 year. Serious and Other (Not Including Serious) Adverse Events monitored/assessed for 100 days after cell infusion."}